Growth-hormone secretagogues and releasing-factor analogues
How GRF analogues and secretagogue peptides are described in endocrine research, and how to read the evidence carefully.
Research use only. For laboratory research use only. Not a drug, food, cosmetic, or medical device. Not for human or veterinary use, diagnostic use, or any form of administration.
Research overview
This class includes analogues of growth-hormone-releasing factor and synthetic secretagogues acting at the ghrelin receptor. Research characterises receptor pharmacology and downstream endocrine signalling.
Molecular characteristics
GRF analogues are modified fragments of the native 44-residue releasing factor. Ipamorelin is a synthetic pentapeptide described as a selective secretagogue.
Areas examined in published research
Receptor binding, pulsatile secretion patterns, and endocrine endpoints in animal and human study populations.
Study designs and model systems
Pituitary cell preparations, rodent endocrine models, and randomised controlled trials in defined clinical populations for certain approved analogues.
In vitro evidence
Cell-based work establishes receptor selectivity and signalling profiles.
Animal-model evidence
Rodent studies characterise secretion dynamics and dose-response relationships in model systems.
Human clinical research
Randomised controlled trials exist for certain approved analogues in specific clinical indications and populations. Those results do not transfer to research-grade material or to other compounds in the class.
Limitations
Class-level statements are frequently over-generalised in secondary sources. Evidence quality varies substantially between individual compounds.
Regulatory status
Material supplied by Batch One is research grade, is not a drug, and is for laboratory research use only.
References
- Falutz J, et al. (2007). Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine.
Human clinical · Randomised controlled trial · source pending verification
Randomised controlled trial of a growth-hormone-releasing factor analogue in a defined patient group.
Limitations: Specific clinical population; not generalisable to other contexts or to laboratory-grade material.
Referenced materials
Last reviewed 2026-08-14 · Research content reviewer, Batch One